KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Medtronic (MDT) over the last 12 years, with Q4 2025 value amounting to -$182.0 million.

  • Medtronic's Change in Accured Expenses fell 7669.9% to -$182.0 million in Q4 2025 from the same period last year, while for Oct 2025 it was $136.0 million, marking a year-over-year decrease of 6449.09%. This contributed to the annual value of $209.0 million for FY2025, which is 4654.73% down from last year.
  • According to the latest figures from Q4 2025, Medtronic's Change in Accured Expenses is -$182.0 million, which was down 7669.9% from -$598.0 million recorded in Q3 2025.
  • Medtronic's 5-year Change in Accured Expenses high stood at $644.0 million for Q2 2024, and its period low was -$673.0 million during Q3 2023.
  • Its 5-year average for Change in Accured Expenses is $57.6 million, with a median of $67.5 million in 2021.
  • As far as peak fluctuations go, Medtronic's Change in Accured Expenses surged by 1025000.0% in 2022, and later crashed by 35782.31% in 2023.
  • Over the past 5 years, Medtronic's Change in Accured Expenses (Quarter) stood at -$30.0 million in 2021, then soared by 543.33% to $133.0 million in 2022, then tumbled by 119.55% to -$26.0 million in 2023, then plummeted by 296.15% to -$103.0 million in 2024, then crashed by 76.7% to -$182.0 million in 2025.
  • Its Change in Accured Expenses was -$182.0 million in Q4 2025, compared to -$598.0 million in Q3 2025 and $366.0 million in Q2 2025.